BioCentury This Week
391 episodes - English - Latest episode: 5 days ago - ★★★★★ - 11 ratingsBioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Ep. 108 - AACR Preview for CAR Ts in Solid Tumors; Plus FDA Weighs in on Data for ALS Ad Com
March 29, 2022 00:00 - 19 minutes - 13.4 MBAACR is just around the corner, and new data being presented at the conference details how stakeholders are improving the specificity of CAR T therapies in solid tumors and improving their ability to penetrate the tumor microenvironment. Plus, BioCentury’s editors discuss the upcoming FDA advisory committee for ALS therapy AMX0035 from Amylyx, including FDA’s stance on the efficacy data and the challenges around weighing the safety of a therapy for a patient community in desperate search of ...
Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
March 22, 2022 00:00 - 20 minutes - 14.4 MBThe importance of FDA’s approval of Bristol Myers' LAG3 inhibitor Opdualag nivolumab/relatlimab for melanoma, the pharma’s disruptive marketing strategy and what’s next among checkpoints in the clinic headline the latest BioCentury This Week podcast. BioCentury's editors also discuss why there’s still a lot of excitement regarding the IL-2 cancer pipeline despite last week’s setback for Nektar Therapeutics and the paths less traveled to raising money as the downturn grinds on. This week’s po...
Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H
March 15, 2022 00:00 - 21 minutes - 15 MBChinese immuno-oncology companies are changing how they interact with FDA as they seek approval of PD-1 programs. On this episode of BioCentury This Week, BioCentury’s editors discuss takeaways from a survey of CEOs and R&D heads developing PD-1 or PD-L1 inhibitors about what’s next for their programs. The team also previews translational data expected at next month’s meeting of the American Association for Cancer Research (AACR) and legislation making its way through Congress as the House E...
Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia
March 08, 2022 00:00 - 22 minutes - 15.4 MBWar Pulls Biotech to Ukraine, Out of Russia: BioCentury's editors look at how the worsening crisis in Ukraine is affecting the global life sciences community, and discuss the challenges and tactics for removing Russian capital from biotech VC funds and the takeaways form a Guest Commentary by 4BIO Capital’s Dima Kuzmin that calls for a thoughtful approach to economic disengagement from Russia. Plus: what highly anticipated TROPiCS-02 data means for Gilead's Trodelvy sacituzumab govitecan-hzi...
Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data
March 01, 2022 01:00 - 22 minutes - 15.3 MBIndustry leaders have vowed to disengage with Russia until it stops its invasion of Ukraine and respects its neighbor’s sovereignty. What's the likely impact of their pledge and what are the implications of the crisis in Ukraine for biopharma companies around the globe? Plus: Assessing the latest cut of data for Intellia's pioneering in vivo CRISPR-Cas9 therapy and key takeaways from Washington Editor Steve Usdin’s conversation with ICER’s Steve Pearson on The BioCentury Show. This week’s po...
Ep. 103 - Califf’s priorities for second stint as FDA Commissioner
February 23, 2022 00:00 - 22 minutes - 15.6 MBNewly confirmed FDA commissioner Rob Califf will be prioritizing a proactive communications strategy, including combating misinformation about science, whilst guiding FDA through the pandemic and trying to keep the agency above Washington’s political fray. Plus, BioCentury’s editors discuss how late-stage investors are adapting to biotech’s bull market and Amgen’s application of its rapid development strategy to its pipeline. Sponsored by Jeito Capital, a global leading investment company wi...
Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner
February 23, 2022 00:00 - 22 minutes - 15.6 MBNewly confirmed FDA commissioner Rob Califf will be prioritizing a proactive communications strategy, including combating misinformation about science, whilst guiding FDA through the pandemic and trying to keep the agency above Washington’s political fray. Plus, BioCentury’s editors discuss how late-stage investors are adapting to biotech’s bull market and Amgen’s application of its rapid development strategy to its pipeline. Sponsored by Jeito Capital, a global leading investment company wi...
Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting
February 15, 2022 01:00 - 20 minutes - 14.4 MBFDA and its advisory panel of oncology experts have repudiated the use of China-only data for regulatory submissions in the U.S. How will China's cancer companies adjust to this new regulatory environment? Plus, BioCentury's editors discuss the upcoming vote on Rob Califf, President Biden's nominee to become the next FDA commissioner, and the latest translational trends in cancer, infectious and neurology as identified BioCentury's Distillery. Sponsored by ICON, the clinical research organiz...
Ep. 101 - Of Biotech Bears, Pazdur & PDUFA
February 08, 2022 02:00 - 28 minutes - 19.7 MBWeathering the bear market. Oncology chief’s change in thinking on PD-1 therapies. Plus BioCentury’s 2021 innovative start-ups. This week’s podcast is sponsored by ICON.
Ep. 100 - Capital markets check in; plus Belgium’s prodigal son returns
February 01, 2022 02:00 - 26 minutes - 18.4 MBThis week’s podcast is sponsored by ICON.
Ep. 99 - Introducing The BioCentury Show, Plus Califf, COVID and GSK
January 25, 2022 02:00 - 26 minutes - 18 MBBioCentury’s new in-depth conversational series launches with Scott Gottlieb as debut guest. This week’s podcast is sponsored by ICON.
Ep. 98 - Bargain Hunting in a Rocky Market, plus Advantage, CMS
January 19, 2022 01:00 - 23 minutes - 16.3 MBPart two of BioCentury’s 2022 Financial Markets Preview, access to Alzheimer’s mAbs, and translational highlights from the Distillery. This week’s podcast is sponsored by ICON.